Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamiparib Combined With Surufatinib as Neoadjuvant Therapy for Advanced Ovarian Cancer
NCT05652283Phase 2Recruiting
- Start
- Nov 2022
- Primary completion
- Mar 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pamiparib and surufatinib in ovarian cancer. Primary endpoint: R0 Resection Rate at 3 months. Started Nov 2022; status: recruiting.
02
Drugs
pamiparibsurufatinib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05652283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05652283.